DOV Pharmaceutical, Inc. Begins Trading on OTC Bull...(l. Such factors may also materially adve...)

-- raise substantial additional capital in order to fund operations;

-- obtain and maintain all necessary patents, licenses and other

intellectual property rights;

-- demonstrate the safety and efficacy of product candidates at each

stage of development;

-- meet our development schedule for our product candidates, including

with respect to clinical trial initiation, enrollment and completion;

-- meet applicable regulatory standards and receive required regulatory

approvals on our anticipated time schedule or at all;

-- meet or require our partners to meet obligations and achieve

milestones under our license and other agreements;

-- maintain collaborations as required with pharmaceutical partners;

-- seek and evaluate strategic alternatives, including with respect to

collaborations and partnerships for certain of our development

programs and compounds; and

-- produce drug candidates in commercial quantities at reasonable costs

and compete successfully against other products and companies.

You should also refer to the risks discussed in our filings with the Securities and Exchange Commission including those contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2006 that was filed on March 30, 2007 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 that was filed on August 8, 2007. We qualify all our forward- looking statements by these cautionary statements. Readers should not place undue reliance on our forward-looking statements. We do not undertake any obligation and do not intend to update any forward-looking statement.